+357 96 030922
info@marketpublishers.com

Global PLLA & PDLLA Aesthetic Injectables Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GE7B895DC9AFEN.html
Date: September 2026
Pages: 117
Price: US$ 4,480.00 (Single User License)
ID: GE7B895DC9AFEN

Abstracts

The global PLLA & PDLLA Aesthetic Injectables market size is expected to reach $ 1428 million by 2032, rising at a market growth of 12.4% CAGR during the forecast period (2026-2032).

PLLA & PDLLA Aesthetic Injectables are professionally administered regenerative aesthetic products formulated with poly-L-lactic acid (PLLA) or poly-D,L-lactic acid (PDLLA) microparticles as the principal collagen-stimulating polymer. These products are delivered by injection into intradermal, deep dermal, subcutaneous, or other indicated soft-tissue layers to support gradual collagen remodeling, improve skin quality, restore facial volume, soften wrinkles and folds, and enhance facial or body contours. Commercial formulations primarily include lyophilized or reconstitutable injectables and ready-to-inject or prefilled presentations. Product architectures range from PLLA/PDLLA combined with functional excipients such as carboxymethyl cellulose and mannitol to composite systems combining PDLLA with hyaluronic acid or other functional components. The market covers finished medical-aesthetic injectable products supplied to licensed aesthetic clinics, dermatology and plastic-surgery practices, hospitals, and other qualified medical institutions, with market value assessed primarily on manufacturer-level product revenue.

Key Findings

Global sales volume of PLLA & PDLLA Aesthetic Injectables was approximately 1.18 million units in 2025

The global average selling price was approximately US$475 per unit in 2025

+357 96 030922
info@marketpublishers.com

PLLA represents the established commercial foundation while PDLLA is expanding rapidly in regenerative and skin-quality applications

Asia Pacific is becoming an increasingly important manufacturing innovation and demand center for regenerative aesthetic injectables

Competition combines established multinational injectable-aesthetics companies with specialized Asian PLLA and PDLLA manufacturers

Market Trends

The PLLA & PDLLA Aesthetic Injectables market is evolving from a traditional facial volumization category toward a broader regenerative-aesthetics platform focused on collagen remodeling, skin quality, firmness, contour restoration, and longer-lasting treatment outcomes. Product innovation increasingly centers on particle engineering, more predictable dispersion, shorter and simpler preparation procedures, reduced injection burden, and formulations designed for different treatment depths. PLLA remains the most established polymer platform, while PDLLA products are broadening the category through differentiated particle structures and composite formulations such as PDLLA combined with hyaluronic acid. The boundary between volumizing fillers and skin-quality biostimulators is consequently becoming less rigid. Established PLLA products are also expanding treatment protocols and geographic availability, while PDLLA manufacturers are increasing international commercialization and physician education. Sculptra continued geographic expansion with its 2025 launch in China after regulatory approval, while JUVELOOK has developed a PDLLA-HA positioning focused on collagen stimulation and skin rejuvenation.

Market Dynamics

Drivers

Demand is being supported by the shift from short-term correction toward treatments that provide gradual tissue remodeling and sustained aesthetic improvement. Growing physician and consumer familiarity with collagen biostimulation is expanding use beyond conventional nasolabial-fold and facial-volume correction into cheek rejuvenation, skin-quality improvement, contour deficiencies, and selected body

+357 96 030922
info@marketpublishers.com

applications. Long clinical experience with established PLLA products also provides an important confidence base for broader adoption; Sculptra, for example, has more than two decades of clinical use and is available across multiple international markets.

Restraints

The market remains constrained by the technical sensitivity of treatment protocols. Product reconstitution, particle dispersion, injection depth, dilution, dosing, patient selection, and post-treatment management can materially influence outcomes. Unlike conventional HA fillers that primarily provide immediate mechanical volume, PLLA and PDLLA products generally depend on progressive biological response, which can make treatment expectations and follow-up more complex. Regulatory requirements for injectable implants, clinical evidence, manufacturing consistency, sterility, particle control, and post-market surveillance also raise market-entry costs for emerging manufacturers.

Opportunities

The strongest opportunities are emerging from expansion into skin-quality improvement, preventive regenerative aesthetics, combination treatment protocols, and body contouring. Product formats that shorten preparation time or provide more consistent handling can increase physician productivity and reduce procedural complexity. Geographic expansion is another important opportunity as established products obtain additional registrations and Asian manufacturers extend PDLLA technologies into international markets. South Korean PDLLA platforms in particular are developing meaningful commercial scale; JUVELOOK surpassed two million vials in cumulative production by September 2025, demonstrating increasing acceptance of PDLLA-based regenerative injectables.

Challenges

Long-term competitive differentiation will depend on more than polymer identity. Manufacturers must demonstrate reproducible particle morphology, controlled biodegradation, injectability, clinical efficacy, safety, manufacturing consistency, and physician-friendly protocols while building sufficient regulatory and clinical evidence. Increasing numbers of regenerative injectables also raise the risk of product homogenization and price competition, particularly in Asian markets. At the same time,

+357 96 030922
info@marketpublishers.com

PLLA and PDLLA products compete for physician budgets and treatment occasions with HA fillers, CaHA biostimulators and other regenerative injectable technologies, requiring suppliers to establish clearly differentiated clinical positioning.

Industry Chain Analysis

The upstream industry chain centers on medical-grade PLLA and PDLLA polymers, polymerization and purification technologies, microsphere or particle-processing capabilities, and formulation components such as carboxymethyl cellulose, mannitol and hyaluronic acid. Packaging materials, sterile containers, lyophilization systems, aseptic processing equipment and analytical testing capabilities are also essential inputs. Polymer molecular characteristics, residual monomer control, particle size distribution, morphology and degradation behavior influence both manufacturing reproducibility and clinical performance, making material engineering and process control important sources of technical differentiation.

Midstream manufacturers convert polymer materials into finished aesthetic injectables through particle preparation, formulation, sterile filling, lyophilization or ready-to-use preparation, quality testing and regulatory validation. Value creation is concentrated in proprietary particle engineering, formulation know-how, reproducible manufacturing, clinical evidence, regulatory approvals and physician education rather than in polymer raw-material cost alone. Downstream products reach licensed aesthetic clinics, dermatology and plastic-surgery practices, hospitals and other qualified medical institutions through direct commercial organizations or authorized distributors. Brand reputation, practitioner training and treatment-protocol standardization materially affect commercialization because clinical outcomes depend partly on injection technique and appropriate patient selection.

Segment Insights

By polymer stereochemistry, the market consists of PLLA-Based Aesthetic Injectables and PDLLA-Based Aesthetic Injectables. PLLA represents the more established commercial segment, supported by long-standing clinical adoption and extensive physician familiarity. PDLLA is developing faster from a smaller base, supported by Asian product innovation and differentiated positioning in skin rejuvenation and collagen stimulation. The commercial distinction is increasingly based on particle design, treatment depth, reconstitution characteristics and desired clinical effect rather than

+357 96 030922
info@marketpublishers.com

polymer name alone.

By formulation architecture, the market spans PLLA/PDLLA with functional excipients, PLLA/PDLLA combined with hyaluronic acid, and products incorporating other functional components. By presentation, lyophilized/reconstitutable injectables remain important, while manufacturers continue to optimize preparation and handling. Injection-depth segmentation ranges from superficial or intradermal treatments focused on skin quality to deep-dermal and subcutaneous treatments designed for volume restoration and contouring. These dimensions create differentiated product opportunities without changing the core PLLA-versus-PDLLA market structure.

Downstream Market Opportunities

Facial aesthetics remains the principal commercial application, but the addressable treatment spectrum is expanding. Volume restoration and wrinkle correction continue to generate core demand, while skin-quality improvement, collagen remodeling and facial contouring are creating additional treatment occasions among patients seeking gradual and natural-looking outcomes. Body applications represent a developing opportunity in selected markets, particularly where regenerative injectables are positioned for contour enhancement, tissue-quality improvement or treatment of localized volume deficiencies. Combination protocols with other injectable or energy-based procedures may further expand physician usage by enabling multi-dimensional aesthetic treatment plans.

Regional Insights

North America and Europe represent mature markets where physician familiarity, established injectable-aesthetics channels and long clinical experience with PLLA support continued demand. Product development increasingly emphasizes broader regenerative claims, refined protocols and expansion beyond conventional facial volumization. Galderma's continuing development of Sculptra illustrates this evolution, including clinical positioning around collagen and elastin remodeling and treatment effects extending beyond simple mechanical filling.

Asia Pacific is the most dynamic competitive region, combining expanding aesthetic demand with a growing manufacturing base for PLLA and PDLLA products. South Korea has emerged as an important PDLLA technology and manufacturing center, while China is attracting both international launches and domestic product development.

+357 96 030922
info@marketpublishers.com

Sculptra entered the Chinese market in April 2025 following NMPA approval, while Korean PDLLA suppliers continue to expand international commercialization. Latin America and the Middle East represent additional expansion opportunities where physician adoption of regenerative aesthetics is increasing, although regulatory pathways, distributor capabilities and premium-product affordability remain important determinants of market development.

Competitive Landscape Analysis

The competitive landscape combines globally established injectable-aesthetics groups with specialized PLLA and PDLLA technology manufacturers. Galderma, through the Sculptra platform and Q-Med manufacturing structure, represents a mature global PLLA position supported by extensive clinical history and international commercialization. South Korean companies including GCS, VAIM and REGEN Biotech have expanded the competitive field through PLLA or PDLLA technologies, differentiated formulations and international distribution, while Chinese manufacturers such as Changchun Shengboma, Puliyan, Meiyan Space and Lepu Medical are increasing domestic product availability. IMEIK's ownership interest in REGEN also illustrates increasing strategic integration between Chinese aesthetic-medical companies and Korean regenerative-injectable technology assets. Competitive advantage is increasingly determined by proprietary particle technology, clinical documentation, manufacturing quality, regulatory registrations, physician education and geographic channel coverage rather than price alone. The market therefore remains technically differentiated even as the number of commercial products increases, with established clinical credibility and reproducible product performance serving as important barriers to entry.

Report Scope

This report studies the global PLLA & PDLLA Aesthetic Injectables production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for PLLA & PDLLA Aesthetic Injectables and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of PLLA & PDLLA Aesthetic Injectables that contribute to its increasing demand across many markets.

+357 96 030922
info@marketpublishers.com

Highlights and key features of the study

Global PLLA & PDLLA Aesthetic Injectables total production and demand, 2021-2032, (K Units)

Global PLLA & PDLLA Aesthetic Injectables total production value, 2021-2032, (USD Million)

Global PLLA & PDLLA Aesthetic Injectables production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)

Global PLLA & PDLLA Aesthetic Injectables consumption by region & country, CAGR, 2021-2032 & (K Units)

U.S. VS China: PLLA & PDLLA Aesthetic Injectables domestic production, consumption, key domestic manufacturers and share

Global PLLA & PDLLA Aesthetic Injectables production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)

Global PLLA & PDLLA Aesthetic Injectables production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

Global PLLA & PDLLA Aesthetic Injectables production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

This report profiles key players in the global PLLA & PDLLA Aesthetic Injectables market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Galderma Group AG, Q-Med AB, GCS Co., Ltd., VAIM Co., Ltd., REGEN Biotech, Inc., IMEIK Technology Development Co., Ltd., Changchun Shengboma Biological Materials Co., Ltd., Puliyan (Nanjing) Medical Technology Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Meiyan Space Biotechnology (Jilin) Co., Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities,

+357 96 030922
info@marketpublishers.com

new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World PLLA & PDLLA Aesthetic Injectables market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global PLLA & PDLLA Aesthetic Injectables Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global PLLA & PDLLA Aesthetic Injectables Market, Segmentation by Type:

+357 96 030922
info@marketpublishers.com

PLLA-Based Aesthetic Injectables

PDLLA-Based Aesthetic Injectables

Global PLLA & PDLLA Aesthetic Injectables Market, Segmentation by Formulation Architecture:

PLLA/PDLLA with Functional Excipients

PLLA/PDLLA with Hyaluronic Acid

PLLA/PDLLA with Other Active Components

Global PLLA & PDLLA Aesthetic Injectables Market, Segmentation by Product Form:

Lyophilized/Reconstitutable Injectables

Ready-to-Inject/Prefilled Injectables

Global PLLA & PDLLA Aesthetic Injectables Market, Segmentation by Application:

Volume Restoration and Contouring

Skin Firmness and Laxity Improvement

Skin Quality and Texture Improvement

Wrinkle and Fold Correction

Others

+357 96 030922
info@marketpublishers.com

Companies Profiled:

Galderma Group AG

Q-Med AB

GCS Co., Ltd.

VAIM Co., Ltd.

REGEN Biotech, Inc.

IMEIK Technology Development Co., Ltd.

Changchun Shengboma Biological Materials Co., Ltd.

Puliyan (Nanjing) Medical Technology Co., Ltd.

Sihuan Pharmaceutical Holdings Group Ltd.

Meiyan Space Biotechnology (Jilin) Co., Ltd.

Lepu Medical Technology (Beijing) Co., Ltd.

Hangzhou Singclean Medical Products Co., Ltd.

Diamond Biotechnology Co., Ltd.

INGAL LLC

Laboratoires Hyamed SA

Key Questions Answered

1. How big is the global PLLA & PDLLA Aesthetic Injectables market?
2. What is the demand of the global PLLA & PDLLA Aesthetic Injectables market?
3. What is the year over year growth of the global PLLA & PDLLA Aesthetic Injectables

+357 96 030922
info@marketpublishers.com

market?
4. What is the total value of the global PLLA & PDLLA Aesthetic Injectables market?
5. Who are the Major Players in the global PLLA & PDLLA Aesthetic Injectables market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 PLLA & PDLLA Aesthetic Injectables Introduction
1.2 World PLLA & PDLLA Aesthetic Injectables Supply & Forecast
  1.2.1 World PLLA & PDLLA Aesthetic Injectables Production Value (2021 & 2025 & 2032)
  1.2.2 World PLLA & PDLLA Aesthetic Injectables Production (2021-2032)
  1.2.3 World PLLA & PDLLA Aesthetic Injectables Pricing Trends (2021-2032)
1.3 World PLLA & PDLLA Aesthetic Injectables Production by Region (Based on Production Site)
  1.3.1 World PLLA & PDLLA Aesthetic Injectables Production Value by Region (2021-2032)
  1.3.2 World PLLA & PDLLA Aesthetic Injectables Production by Region (2021-2032)
  1.3.3 World PLLA & PDLLA Aesthetic Injectables Average Price by Region (2021-2032)
  1.3.4 North America PLLA & PDLLA Aesthetic Injectables Production (2021-2032)
  1.3.5 Europe PLLA & PDLLA Aesthetic Injectables Production (2021-2032)
  1.3.6 China PLLA & PDLLA Aesthetic Injectables Production (2021-2032)
  1.3.7 Japan PLLA & PDLLA Aesthetic Injectables Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 PLLA & PDLLA Aesthetic Injectables Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 PLLA & PDLLA Aesthetic Injectables Major Market Trends

2 DEMAND SUMMARY

2.1 World PLLA & PDLLA Aesthetic Injectables Demand (2021-2032)
2.2 World PLLA & PDLLA Aesthetic Injectables Consumption by Region
  2.2.1 World PLLA & PDLLA Aesthetic Injectables Consumption by Region (2021-2026)
  2.2.2 World PLLA & PDLLA Aesthetic Injectables Consumption Forecast by Region (2027-2032)
2.3 United States PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)
2.4 China PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)
2.5 Europe PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)
2.6 Japan PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)
2.7 South Korea PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)
2.8 ASEAN PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)

+357 96 030922
info@marketpublishers.com

2.9 India PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World PLLA & PDLLA Aesthetic Injectables Production Value by Manufacturer (2021-2026)
3.2 World PLLA & PDLLA Aesthetic Injectables Production by Manufacturer (2021-2026)
3.3 World PLLA & PDLLA Aesthetic Injectables Average Price by Manufacturer (2021-2026)
3.4 PLLA & PDLLA Aesthetic Injectables Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global PLLA & PDLLA Aesthetic Injectables Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for PLLA & PDLLA Aesthetic Injectables in 2025
  3.5.3 Global Concentration Ratios (CR8) for PLLA & PDLLA Aesthetic Injectables in 2025
3.6 PLLA & PDLLA Aesthetic Injectables Market: Overall Company Footprint Analysis
  3.6.1 PLLA & PDLLA Aesthetic Injectables Market: Region Footprint
  3.6.2 PLLA & PDLLA Aesthetic Injectables Market: Company Product Type Footprint
  3.6.3 PLLA & PDLLA Aesthetic Injectables Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: PLLA & PDLLA Aesthetic Injectables Production Value Comparison
  4.1.1 United States VS China: PLLA & PDLLA Aesthetic Injectables Production Value Comparison (2021 & 2025 & 2032)
  4.1.2 United States VS China: PLLA & PDLLA Aesthetic Injectables Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: PLLA & PDLLA Aesthetic Injectables Production

+357 96 030922
info@marketpublishers.com

Comparison
4.2.1 United States VS China: PLLA & PDLLA Aesthetic Injectables Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: PLLA & PDLLA Aesthetic Injectables Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: PLLA & PDLLA Aesthetic Injectables Consumption Comparison
4.3.1 United States VS China: PLLA & PDLLA Aesthetic Injectables Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: PLLA & PDLLA Aesthetic Injectables Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based PLLA & PDLLA Aesthetic Injectables Manufacturers and Market Share, 2021-2026
4.4.1 United States Based PLLA & PDLLA Aesthetic Injectables Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value (2021-2026)
4.4.3 United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production (2021-2026)
4.5 China Based PLLA & PDLLA Aesthetic Injectables Manufacturers and Market Share
4.5.1 China Based PLLA & PDLLA Aesthetic Injectables Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value (2021-2026)
4.5.3 China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production (2021-2026)
4.6 Rest of World Based PLLA & PDLLA Aesthetic Injectables Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based PLLA & PDLLA Aesthetic Injectables Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World PLLA & PDLLA Aesthetic Injectables Market Size Overview by Type: 2021 VS 2025 VS 2032

+357 96 030922
info@marketpublishers.com

5.2 Segment Introduction by Type
5.2.1 PLLA-Based Aesthetic Injectables
5.2.2 PDLLA-Based Aesthetic Injectables
5.3 Market Segment by Type
5.3.1 World PLLA & PDLLA Aesthetic Injectables Production by Type (2021-2032)
5.3.2 World PLLA & PDLLA Aesthetic Injectables Production Value by Type (2021-2032)
5.3.3 World PLLA & PDLLA Aesthetic Injectables Average Price by Type (2021-2032)

6 MARKET ANALYSIS BY FORMULATION ARCHITECTURE

6.1 World PLLA & PDLLA Aesthetic Injectables Market Size Overview by Formulation Architecture: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Formulation Architecture
6.2.1 PLLA/PDLLA with Functional Excipients
6.2.2 PLLA/PDLLA with Hyaluronic Acid
6.2.3 PLLA/PDLLA with Other Active Components
6.3 Market Segment by Formulation Architecture
6.3.1 World PLLA & PDLLA Aesthetic Injectables Production by Formulation Architecture (2021-2032)
6.3.2 World PLLA & PDLLA Aesthetic Injectables Production Value by Formulation Architecture (2021-2032)
6.3.3 World PLLA & PDLLA Aesthetic Injectables Average Price by Formulation Architecture (2021-2032)

7 MARKET ANALYSIS BY PRODUCT FORM

7.1 World PLLA & PDLLA Aesthetic Injectables Market Size Overview by Product Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Product Form
7.2.1 Lyophilized/Reconstitutable Injectables
7.2.2 Ready-to-Inject/Prefilled Injectables
7.3 Market Segment by Product Form
7.3.1 World PLLA & PDLLA Aesthetic Injectables Production by Product Form (2021-2032)
7.3.2 World PLLA & PDLLA Aesthetic Injectables Production Value by Product Form (2021-2032)
7.3.3 World PLLA & PDLLA Aesthetic Injectables Average Price by Product Form (2021-2032)

+357 96 030922
info@marketpublishers.com

8 MARKET ANALYSIS BY APPLICATION

8.1 World PLLA & PDLLA Aesthetic Injectables Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
  8.2.1 Volume Restoration and Contouring
  8.2.2 Skin Firmness and Laxity Improvement
  8.2.3 Skin Quality and Texture Improvement
  8.2.4 Wrinkle and Fold Correction
  8.2.5 Others
8.3 Market Segment by Application
  8.3.1 World PLLA & PDLLA Aesthetic Injectables Production by Application (2021-2032)
  8.3.2 World PLLA & PDLLA Aesthetic Injectables Production Value by Application (2021-2032)
  8.3.3 World PLLA & PDLLA Aesthetic Injectables Average Price by Application (2021-2032)

9 COMPANY PROFILES

9.1 Galderma Group AG
  9.1.1 Galderma Group AG Details
  9.1.2 Galderma Group AG Major Business
  9.1.3 Galderma Group AG PLLA & PDLLA Aesthetic Injectables Product and Services
  9.1.4 Galderma Group AG PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.1.5 Galderma Group AG Recent Developments/Updates
  9.1.6 Galderma Group AG Competitive Strengths & Weaknesses
9.2 Q-Med AB
  9.2.1 Q-Med AB Details
  9.2.2 Q-Med AB Major Business
  9.2.3 Q-Med AB PLLA & PDLLA Aesthetic Injectables Product and Services
  9.2.4 Q-Med AB PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.2.5 Q-Med AB Recent Developments/Updates
  9.2.6 Q-Med AB Competitive Strengths & Weaknesses
9.3 GCS Co., Ltd.
  9.3.1 GCS Co., Ltd. Details

+357 96 030922
info@marketpublishers.com

9.3.2 GCS Co., Ltd. Major Business
9.3.3 GCS Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.3.4 GCS Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 GCS Co., Ltd. Recent Developments/Updates
9.3.6 GCS Co., Ltd. Competitive Strengths & Weaknesses
9.4 VAIM Co., Ltd.
9.4.1 VAIM Co., Ltd. Details
9.4.2 VAIM Co., Ltd. Major Business
9.4.3 VAIM Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.4.4 VAIM Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 VAIM Co., Ltd. Recent Developments/Updates
9.4.6 VAIM Co., Ltd. Competitive Strengths & Weaknesses
9.5 REGEN Biotech, Inc.
9.5.1 REGEN Biotech, Inc. Details
9.5.2 REGEN Biotech, Inc. Major Business
9.5.3 REGEN Biotech, Inc. PLLA & PDLLA Aesthetic Injectables Product and Services
9.5.4 REGEN Biotech, Inc. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 REGEN Biotech, Inc. Recent Developments/Updates
9.5.6 REGEN Biotech, Inc. Competitive Strengths & Weaknesses
9.6 IMEIK Technology Development Co., Ltd.
9.6.1 IMEIK Technology Development Co., Ltd. Details
9.6.2 IMEIK Technology Development Co., Ltd. Major Business
9.6.3 IMEIK Technology Development Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.6.4 IMEIK Technology Development Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 IMEIK Technology Development Co., Ltd. Recent Developments/Updates
9.6.6 IMEIK Technology Development Co., Ltd. Competitive Strengths & Weaknesses
9.7 Changchun Shengboma Biological Materials Co., Ltd.
9.7.1 Changchun Shengboma Biological Materials Co., Ltd. Details
9.7.2 Changchun Shengboma Biological Materials Co., Ltd. Major Business
9.7.3 Changchun Shengboma Biological Materials Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.7.4 Changchun Shengboma Biological Materials Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Changchun Shengboma Biological Materials Co., Ltd. Recent

+357 96 030922
info@marketpublishers.com

Developments/Updates
9.7.6 Changchun Shengboma Biological Materials Co., Ltd. Competitive Strengths & Weaknesses
9.8 Puliyan (Nanjing) Medical Technology Co., Ltd.
9.8.1 Puliyan (Nanjing) Medical Technology Co., Ltd. Details
9.8.2 Puliyan (Nanjing) Medical Technology Co., Ltd. Major Business
9.8.3 Puliyan (Nanjing) Medical Technology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.8.4 Puliyan (Nanjing) Medical Technology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Puliyan (Nanjing) Medical Technology Co., Ltd. Recent Developments/Updates
9.8.6 Puliyan (Nanjing) Medical Technology Co., Ltd. Competitive Strengths & Weaknesses
9.9 Sihuan Pharmaceutical Holdings Group Ltd.
9.9.1 Sihuan Pharmaceutical Holdings Group Ltd. Details
9.9.2 Sihuan Pharmaceutical Holdings Group Ltd. Major Business
9.9.3 Sihuan Pharmaceutical Holdings Group Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.9.4 Sihuan Pharmaceutical Holdings Group Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Sihuan Pharmaceutical Holdings Group Ltd. Recent Developments/Updates
9.9.6 Sihuan Pharmaceutical Holdings Group Ltd. Competitive Strengths & Weaknesses
9.10 Meiyan Space Biotechnology (Jilin) Co., Ltd.
9.10.1 Meiyan Space Biotechnology (Jilin) Co., Ltd. Details
9.10.2 Meiyan Space Biotechnology (Jilin) Co., Ltd. Major Business
9.10.3 Meiyan Space Biotechnology (Jilin) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.10.4 Meiyan Space Biotechnology (Jilin) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Meiyan Space Biotechnology (Jilin) Co., Ltd. Recent Developments/Updates
9.10.6 Meiyan Space Biotechnology (Jilin) Co., Ltd. Competitive Strengths & Weaknesses
9.11 Lepu Medical Technology (Beijing) Co., Ltd.
9.11.1 Lepu Medical Technology (Beijing) Co., Ltd. Details
9.11.2 Lepu Medical Technology (Beijing) Co., Ltd. Major Business
9.11.3 Lepu Medical Technology (Beijing) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.11.4 Lepu Medical Technology (Beijing) Co., Ltd. PLLA & PDLLA Aesthetic

+357 96 030922
info@marketpublishers.com

Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Lepu Medical Technology (Beijing) Co., Ltd. Recent Developments/Updates
9.11.6 Lepu Medical Technology (Beijing) Co., Ltd. Competitive Strengths & Weaknesses
9.12 Hangzhou Singclean Medical Products Co., Ltd.
9.12.1 Hangzhou Singclean Medical Products Co., Ltd. Details
9.12.2 Hangzhou Singclean Medical Products Co., Ltd. Major Business
9.12.3 Hangzhou Singclean Medical Products Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.12.4 Hangzhou Singclean Medical Products Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Hangzhou Singclean Medical Products Co., Ltd. Recent Developments/Updates
9.12.6 Hangzhou Singclean Medical Products Co., Ltd. Competitive Strengths & Weaknesses
9.13 Diamond Biotechnology Co., Ltd.
9.13.1 Diamond Biotechnology Co., Ltd. Details
9.13.2 Diamond Biotechnology Co., Ltd. Major Business
9.13.3 Diamond Biotechnology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
9.13.4 Diamond Biotechnology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Diamond Biotechnology Co., Ltd. Recent Developments/Updates
9.13.6 Diamond Biotechnology Co., Ltd. Competitive Strengths & Weaknesses
9.14 INGAL LLC
9.14.1 INGAL LLC Details
9.14.2 INGAL LLC Major Business
9.14.3 INGAL LLC PLLA & PDLLA Aesthetic Injectables Product and Services
9.14.4 INGAL LLC PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 INGAL LLC Recent Developments/Updates
9.14.6 INGAL LLC Competitive Strengths & Weaknesses
9.15 Laboratoires Hyamed SA
9.15.1 Laboratoires Hyamed SA Details
9.15.2 Laboratoires Hyamed SA Major Business
9.15.3 Laboratoires Hyamed SA PLLA & PDLLA Aesthetic Injectables Product and Services
9.15.4 Laboratoires Hyamed SA PLLA & PDLLA Aesthetic Injectables Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Laboratoires Hyamed SA Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.15.6 Laboratoires Hyamed SA Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 PLLA & PDLLA Aesthetic Injectables Industry Chain
10.2 PLLA & PDLLA Aesthetic Injectables Upstream Analysis
10.2.1 PLLA & PDLLA Aesthetic Injectables Core Raw Materials
10.2.2 Main Manufacturers of PLLA & PDLLA Aesthetic Injectables Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 PLLA & PDLLA Aesthetic Injectables Production Mode
10.6 PLLA & PDLLA Aesthetic Injectables Procurement Model
10.7 PLLA & PDLLA Aesthetic Injectables Industry Sales Model and Sales Channels
10.7.1 PLLA & PDLLA Aesthetic Injectables Sales Model
10.7.2 PLLA & PDLLA Aesthetic Injectables Typical Distributors

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World PLLA & PDLLA Aesthetic Injectables Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World PLLA & PDLLA Aesthetic Injectables Production Value by Region (2021-2026) & (USD Million)
Table 3. World PLLA & PDLLA Aesthetic Injectables Production Value by Region (2027-2032) & (USD Million)
Table 4. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Region (2021-2026)
Table 5. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Region (2027-2032)
Table 6. World PLLA & PDLLA Aesthetic Injectables Production by Region (2021-2026) & (K Units)
Table 7. World PLLA & PDLLA Aesthetic Injectables Production by Region (2027-2032) & (K Units)
Table 8. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Region (2021-2026)
Table 9. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Region (2027-2032)
Table 10. World PLLA & PDLLA Aesthetic Injectables Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World PLLA & PDLLA Aesthetic Injectables Average Price by Region (2027-2032) & (US$/Unit)
Table 12. PLLA & PDLLA Aesthetic Injectables Major Market Trends
Table 13. World PLLA & PDLLA Aesthetic Injectables Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World PLLA & PDLLA Aesthetic Injectables Consumption by Region (2021-2026) & (K Units)
Table 15. World PLLA & PDLLA Aesthetic Injectables Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World PLLA & PDLLA Aesthetic Injectables Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key PLLA & PDLLA Aesthetic Injectables Producers in 2025
Table 18. World PLLA & PDLLA Aesthetic Injectables Production by Manufacturer (2021-2026) & (K Units)

+357 96 030922
info@marketpublishers.com

Table 19. Production Market Share of Key PLLA & PDLLA Aesthetic Injectables Producers in 2025
Table 20. World PLLA & PDLLA Aesthetic Injectables Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global PLLA & PDLLA Aesthetic Injectables Company Evaluation Quadrant
Table 22. World PLLA & PDLLA Aesthetic Injectables Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and PLLA & PDLLA Aesthetic Injectables Production Site of Key Manufacturer
Table 24. PLLA & PDLLA Aesthetic Injectables Market: Company Product Type Footprint
Table 25. PLLA & PDLLA Aesthetic Injectables Market: Company Product Application Footprint
Table 26. PLLA & PDLLA Aesthetic Injectables Competitive Factors
Table 27. PLLA & PDLLA Aesthetic Injectables New Entrant and Capacity Expansion Plans
Table 28. PLLA & PDLLA Aesthetic Injectables Mergers & Acquisitions Activity
Table 29. United States VS China PLLA & PDLLA Aesthetic Injectables Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China PLLA & PDLLA Aesthetic Injectables Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China PLLA & PDLLA Aesthetic Injectables Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based PLLA & PDLLA Aesthetic Injectables Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Market Share (2021-2026)
Table 37. China Based PLLA & PDLLA Aesthetic Injectables Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 40. China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Market Share (2021-2026)
Table 42. Rest of World Based PLLA & PDLLA Aesthetic Injectables Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Market Share (2021-2026)
Table 47. World PLLA & PDLLA Aesthetic Injectables Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World PLLA & PDLLA Aesthetic Injectables Production by Type (2021-2026) & (K Units)
Table 49. World PLLA & PDLLA Aesthetic Injectables Production by Type (2027-2032) & (K Units)
Table 50. World PLLA & PDLLA Aesthetic Injectables Production Value by Type (2021-2026) & (USD Million)
Table 51. World PLLA & PDLLA Aesthetic Injectables Production Value by Type (2027-2032) & (USD Million)
Table 52. World PLLA & PDLLA Aesthetic Injectables Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World PLLA & PDLLA Aesthetic Injectables Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World PLLA & PDLLA Aesthetic Injectables Production Value by Formulation Architecture, (USD Million), 2021 & 2025 & 2032
Table 55. World PLLA & PDLLA Aesthetic Injectables Production by Formulation Architecture (2021-2026) & (K Units)
Table 56. World PLLA & PDLLA Aesthetic Injectables Production by Formulation Architecture (2027-2032) & (K Units)
Table 57. World PLLA & PDLLA Aesthetic Injectables Production Value by Formulation Architecture (2021-2026) & (USD Million)
Table 58. World PLLA & PDLLA Aesthetic Injectables Production Value by Formulation Architecture (2027-2032) & (USD Million)
Table 59. World PLLA & PDLLA Aesthetic Injectables Average Price by Formulation

+357 96 030922
info@marketpublishers.com

Architecture (2021-2026) & (US$/Unit)
Table 60. World PLLA & PDLLA Aesthetic Injectables Average Price by Formulation Architecture (2027-2032) & (US$/Unit)
Table 61. World PLLA & PDLLA Aesthetic Injectables Production Value by Product Form, (USD Million), 2021 & 2025 & 2032
Table 62. World PLLA & PDLLA Aesthetic Injectables Production by Product Form (2021-2026) & (K Units)
Table 63. World PLLA & PDLLA Aesthetic Injectables Production by Product Form (2027-2032) & (K Units)
Table 64. World PLLA & PDLLA Aesthetic Injectables Production Value by Product Form (2021-2026) & (USD Million)
Table 65. World PLLA & PDLLA Aesthetic Injectables Production Value by Product Form (2027-2032) & (USD Million)
Table 66. World PLLA & PDLLA Aesthetic Injectables Average Price by Product Form (2021-2026) & (US$/Unit)
Table 67. World PLLA & PDLLA Aesthetic Injectables Average Price by Product Form (2027-2032) & (US$/Unit)
Table 68. World PLLA & PDLLA Aesthetic Injectables Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World PLLA & PDLLA Aesthetic Injectables Production by Application (2021-2026) & (K Units)
Table 70. World PLLA & PDLLA Aesthetic Injectables Production by Application (2027-2032) & (K Units)
Table 71. World PLLA & PDLLA Aesthetic Injectables Production Value by Application (2021-2026) & (USD Million)
Table 72. World PLLA & PDLLA Aesthetic Injectables Production Value by Application (2027-2032) & (USD Million)
Table 73. World PLLA & PDLLA Aesthetic Injectables Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World PLLA & PDLLA Aesthetic Injectables Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Galderma Group AG Basic Information, Manufacturing Base and Competitors
Table 76. Galderma Group AG Major Business
Table 77. Galderma Group AG PLLA & PDLLA Aesthetic Injectables Product and Services
Table 78. Galderma Group AG PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Galderma Group AG Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

Table 80. Galderma Group AG Competitive Strengths & Weaknesses
Table 81. Q-Med AB Basic Information, Manufacturing Base and Competitors
Table 82. Q-Med AB Major Business
Table 83. Q-Med AB PLLA & PDLLA Aesthetic Injectables Product and Services
Table 84. Q-Med AB PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Q-Med AB Recent Developments/Updates
Table 86. Q-Med AB Competitive Strengths & Weaknesses
Table 87. GCS Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 88. GCS Co., Ltd. Major Business
Table 89. GCS Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 90. GCS Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. GCS Co., Ltd. Recent Developments/Updates
Table 92. GCS Co., Ltd. Competitive Strengths & Weaknesses
Table 93. VAIM Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 94. VAIM Co., Ltd. Major Business
Table 95. VAIM Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 96. VAIM Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. VAIM Co., Ltd. Recent Developments/Updates
Table 98. VAIM Co., Ltd. Competitive Strengths & Weaknesses
Table 99. REGEN Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 100. REGEN Biotech, Inc. Major Business
Table 101. REGEN Biotech, Inc. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 102. REGEN Biotech, Inc. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. REGEN Biotech, Inc. Recent Developments/Updates
Table 104. REGEN Biotech, Inc. Competitive Strengths & Weaknesses
Table 105. IMEIK Technology Development Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 106. IMEIK Technology Development Co., Ltd. Major Business
Table 107. IMEIK Technology Development Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services

+357 96 030922
info@marketpublishers.com

Table 108. IMEIK Technology Development Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. IMEIK Technology Development Co., Ltd. Recent Developments/Updates
Table 110. IMEIK Technology Development Co., Ltd. Competitive Strengths & Weaknesses
Table 111. Changchun Shengboma Biological Materials Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 112. Changchun Shengboma Biological Materials Co., Ltd. Major Business
Table 113. Changchun Shengboma Biological Materials Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 114. Changchun Shengboma Biological Materials Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Changchun Shengboma Biological Materials Co., Ltd. Recent Developments/Updates
Table 116. Changchun Shengboma Biological Materials Co., Ltd. Competitive Strengths & Weaknesses
Table 117. Puliyan (Nanjing) Medical Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 118. Puliyan (Nanjing) Medical Technology Co., Ltd. Major Business
Table 119. Puliyan (Nanjing) Medical Technology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 120. Puliyan (Nanjing) Medical Technology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Puliyan (Nanjing) Medical Technology Co., Ltd. Recent Developments/Updates
Table 122. Puliyan (Nanjing) Medical Technology Co., Ltd. Competitive Strengths & Weaknesses
Table 123. Sihuan Pharmaceutical Holdings Group Ltd. Basic Information, Manufacturing Base and Competitors
Table 124. Sihuan Pharmaceutical Holdings Group Ltd. Major Business
Table 125. Sihuan Pharmaceutical Holdings Group Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 126. Sihuan Pharmaceutical Holdings Group Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Sihuan Pharmaceutical Holdings Group Ltd. Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

Table 128. Sihuan Pharmaceutical Holdings Group Ltd. Competitive Strengths & Weaknesses
Table 129. Meiyan Space Biotechnology (Jilin) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 130. Meiyan Space Biotechnology (Jilin) Co., Ltd. Major Business
Table 131. Meiyan Space Biotechnology (Jilin) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 132. Meiyan Space Biotechnology (Jilin) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Meiyan Space Biotechnology (Jilin) Co., Ltd. Recent Developments/Updates
Table 134. Meiyan Space Biotechnology (Jilin) Co., Ltd. Competitive Strengths & Weaknesses
Table 135. Lepu Medical Technology (Beijing) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 136. Lepu Medical Technology (Beijing) Co., Ltd. Major Business
Table 137. Lepu Medical Technology (Beijing) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 138. Lepu Medical Technology (Beijing) Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Lepu Medical Technology (Beijing) Co., Ltd. Recent Developments/Updates
Table 140. Lepu Medical Technology (Beijing) Co., Ltd. Competitive Strengths & Weaknesses
Table 141. Hangzhou Singclean Medical Products Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 142. Hangzhou Singclean Medical Products Co., Ltd. Major Business
Table 143. Hangzhou Singclean Medical Products Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 144. Hangzhou Singclean Medical Products Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Hangzhou Singclean Medical Products Co., Ltd. Recent Developments/Updates
Table 146. Hangzhou Singclean Medical Products Co., Ltd. Competitive Strengths & Weaknesses
Table 147. Diamond Biotechnology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 148. Diamond Biotechnology Co., Ltd. Major Business

+357 96 030922
info@marketpublishers.com

Table 149. Diamond Biotechnology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Product and Services
Table 150. Diamond Biotechnology Co., Ltd. PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Diamond Biotechnology Co., Ltd. Recent Developments/Updates
Table 152. Diamond Biotechnology Co., Ltd. Competitive Strengths & Weaknesses
Table 153. INGAL LLC Basic Information, Manufacturing Base and Competitors
Table 154. INGAL LLC Major Business
Table 155. INGAL LLC PLLA & PDLLA Aesthetic Injectables Product and Services
Table 156. INGAL LLC PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. INGAL LLC Recent Developments/Updates
Table 158. INGAL LLC Competitive Strengths & Weaknesses
Table 159. Laboratoires Hyamed SA Basic Information, Manufacturing Base and Competitors
Table 160. Laboratoires Hyamed SA Major Business
Table 161. Laboratoires Hyamed SA PLLA & PDLLA Aesthetic Injectables Product and Services
Table 162. Laboratoires Hyamed SA PLLA & PDLLA Aesthetic Injectables Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Laboratoires Hyamed SA Recent Developments/Updates
Table 164. Laboratoires Hyamed SA Competitive Strengths & Weaknesses
Table 165. Global Key Players of PLLA & PDLLA Aesthetic Injectables Upstream (Raw Materials)
Table 166. Global PLLA & PDLLA Aesthetic Injectables Typical Customers
Table 167. PLLA & PDLLA Aesthetic Injectables Typical Distributors

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. PLLA & PDLLA Aesthetic Injectables Picture
Figure 2. World PLLA & PDLLA Aesthetic Injectables Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World PLLA & PDLLA Aesthetic Injectables Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World PLLA & PDLLA Aesthetic Injectables Production (2021-2032) & (K Units)
Figure 5. World PLLA & PDLLA Aesthetic Injectables Average Price (2021-2032) & (US$/Unit)
Figure 6. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Region (2021-2032)
Figure 7. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Region (2021-2032)
Figure 8. North America PLLA & PDLLA Aesthetic Injectables Production (2021-2032) & (K Units)
Figure 9. Europe PLLA & PDLLA Aesthetic Injectables Production (2021-2032) & (K Units)
Figure 10. China PLLA & PDLLA Aesthetic Injectables Production (2021-2032) & (K Units)
Figure 11. Japan PLLA & PDLLA Aesthetic Injectables Production (2021-2032) & (K Units)
Figure 12. PLLA & PDLLA Aesthetic Injectables Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 15. World PLLA & PDLLA Aesthetic Injectables Consumption Market Share by Region (2021-2032)
Figure 16. United States PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 17. China PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 18. Europe PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 19. Japan PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)

+357 96 030922
info@marketpublishers.com

Figure 20. South Korea PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 21. ASEAN PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 22. India PLLA & PDLLA Aesthetic Injectables Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of PLLA & PDLLA Aesthetic Injectables by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for PLLA & PDLLA Aesthetic Injectables Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for PLLA & PDLLA Aesthetic Injectables Markets in 2025
Figure 26. United States VS China: PLLA & PDLLA Aesthetic Injectables Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: PLLA & PDLLA Aesthetic Injectables Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: PLLA & PDLLA Aesthetic Injectables Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Market Share 2025
Figure 30. China Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Market Share 2025
Figure 31. Rest of World Based Manufacturers PLLA & PDLLA Aesthetic Injectables Production Market Share 2025
Figure 32. World PLLA & PDLLA Aesthetic Injectables Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Type in 2025
Figure 34. PLLA-Based Aesthetic Injectables
Figure 35. PDLLA-Based Aesthetic Injectables
Figure 36. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Type (2021-2032)
Figure 37. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Type (2021-2032)
Figure 38. World PLLA & PDLLA Aesthetic Injectables Average Price by Type (2021-2032) & (US$/Unit)
Figure 39. World PLLA & PDLLA Aesthetic Injectables Production Value by Formulation Architecture, (USD Million), 2021 & 2025 & 2032
Figure 40. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share

+357 96 030922
info@marketpublishers.com

by Formulation Architecture in 2025
Figure 41. PLLA/PDLLA with Functional Excipients
Figure 42. PLLA/PDLLA with Hyaluronic Acid
Figure 43. PLLA/PDLLA with Other Active Components
Figure 44. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Formulation Architecture (2021-2032)
Figure 45. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Formulation Architecture (2021-2032)
Figure 46. World PLLA & PDLLA Aesthetic Injectables Average Price by Formulation Architecture (2021-2032) & (US$/Unit)
Figure 47. World PLLA & PDLLA Aesthetic Injectables Production Value by Product Form, (USD Million), 2021 & 2025 & 2032
Figure 48. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Product Form in 2025
Figure 49. Lyophilized/Reconstitutable Injectables
Figure 50. Ready-to-Inject/Prefilled Injectables
Figure 51. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Product Form (2021-2032)
Figure 52. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Product Form (2021-2032)
Figure 53. World PLLA & PDLLA Aesthetic Injectables Average Price by Product Form (2021-2032) & (US$/Unit)
Figure 54. World PLLA & PDLLA Aesthetic Injectables Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Application in 2025
Figure 56. Volume Restoration and Contouring
Figure 57. Skin Firmness and Laxity Improvement
Figure 58. Skin Quality and Texture Improvement
Figure 59. Wrinkle and Fold Correction
Figure 60. Others
Figure 61. World PLLA & PDLLA Aesthetic Injectables Production Market Share by Application (2021-2032)
Figure 62. World PLLA & PDLLA Aesthetic Injectables Production Value Market Share by Application (2021-2032)
Figure 63. World PLLA & PDLLA Aesthetic Injectables Average Price by Application (2021-2032) & (US$/Unit)
Figure 64. PLLA & PDLLA Aesthetic Injectables Industry Chain
Figure 65. PLLA & PDLLA Aesthetic Injectables Procurement Model

+357 96 030922
info@marketpublishers.com

Figure 66. PLLA & PDLLA Aesthetic Injectables Sales Model
Figure 67. PLLA & PDLLA Aesthetic Injectables Sales Channels, Direct Sales, and Distribution
Figure 68. Methodology
Figure 69. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global PLLA & PDLLA Aesthetic Injectables Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GE7B895DC9AFEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE7B895DC9AFEN.html